Atlas Trials

Cholangiocarcinoma, Intrahepatic

21 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Cholangiocarcinoma, Intrahepatic

RecordFirmDate
Percutaneous Cholangiopancreatoscopy Registry (NCT05210322)Johns Hopkins University2022-01-01
PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment (NCT04634058)Shanghai Zhongshan Hospital2021-03-26
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence (NCT04782804)Fudan University2021-01-01
Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma (NCT04527679)Shanghai Zhongshan Hospital2020-10-01
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors (NCT04506281)Shanghai Zhongshan Hospital2020-08-10
Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment (NCT04264260)Kaohsiung Medical University Chung-Ho Memorial Hospital2019-12-24
Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma (NCT04195503)University Health Network, Toronto2019-12-10
Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma (NCT04077983)Shanghai Zhongshan Hospital2019-09-01
Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma (NCT03951597)Shanghai Zhongshan Hospital2019-05-10
Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study (NCT03405909)University Hospital Erlangen2018-04-21
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma (NCT03377179)RedHill Biopharma Limited2018-03-07
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma (NCT03267940)Halozyme Therapeutics2017-10-02
Surgery for Recurrent Intrahepatic Cholangiocarcinoma (NCT04072250)Chang Gung Memorial Hospital2017-06-01

Track Cholangiocarcinoma, Intrahepatic automatically

Every clearance here is in the API, with alerts when new ones post.